Atreca Stock
Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.
Sign up today and learn more about Atreca Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Atreca Stock
Atreca is a biopharmaceutical company whose Immune Repertoire Capture™ technology revolutionizes the discovery and development of a wide range of products.
Funding History
| October 2011 | $160K |
|---|---|
| September 2012 | $6.0M |
| August 2013 | $700K |
| November 2015 | $56.0M |
| August 2017 | $35.0M |
| September 2018 | $125M |
Management
Co-Founder , Senior Vice President & Corporate Development
Paulette Dillon
Co-founder , Vice President & Research
Daniel Emerling
Co-Founder & Chief Technologist
Yann Chong Tan
Co-Founder , President, CEO & Chief Scientific Officer
Tito A Serafini
Co-founder & CTO
Guy Cavet
Co-founder , Vice President, Informatics and Information Technology
Wayne Volkmuth
Co-founder , Vice President, Finance and Operations
Jonathan Woo
Chief Scientific Officer and Senior Vice President
Norman Greenberg
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
